Treatment of sarcoidosis

Seminars in Respiratory and Critical Care Medicine

Volumn 31, Issue 4, 2010, Pages 501-518

  Lazar, Catherine A ^a   Culver, Daniel A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

corticosteroids; immunomodulators; immunosuppressive medications; Sarcoidosis; therapy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXMETHYLPHENIDATE; ETANERCEPT; FLUTICASONE; GLUCOCORTICOID; GOLIMUMAB; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MODAFINIL; MYCOPHENOLIC ACID; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; THALIDOMIDE;

ALOPECIA; ANEMIA; ANOREXIA; BLADDER CANCER; CARDIOMYOPATHY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DRUG MEGADOSE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; INFLAMMATION; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHOMA; MYOPATHY; NAUSEA; NEOPLASM; NEUROPATHY; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RETINOPATHY; REVIEW; SARCOIDOSIS; SIDE EFFECT; SOMNOLENCE; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; IMMUNOLOGY; PATHOPHYSIOLOGY;

GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; PHENOTYPE; QUALITY OF LIFE; SARCOIDOSIS;

EID: 77955032524     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0030-1262218     Document Type: Review

References (166)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999 160 736-755
2. Judson M A., Baughman R P., Thompson B W. et al, ACCESS Research Group. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003 20 204-211
3. Sones M, Israel H L., Dratman M B., Frank J H. Effect of cortisone in sarcoidosis. N Engl J Med 1951 244 209-213
4. Siltzbach L E. Effects of cortisone in sarcoidosis; a study of thirteen patients. Am J Med 1952 12 139-160
5. Lynch J P. III, Ma Y L., Koss M N., White E S. Pulmonary sarcoidosis. Semin Respir Crit Care Med 2007 28 53-74
6. Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther 1996 10 495-510
7. Cox C E., Donohue J F., Brown C D., Kataria Y P., Judson M A. Health-related quality of life of persons with sarcoidosis. Chest 2004 125 997-1004
8. Baughman R P., Sparkman B K., Lower E E. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007 132 207-213
9. Davidson T A., Caldwell E S., Curtis J R., Hudson L D., Steinberg K P. Reduced quality of life in survivors of acute respiratory distress syndrome compared with critically ill control patients. JAMA 1999 281 354-360
10. Bing E G., Hays R D., Jacobson L P. et al. Health-related quality of life among people with HIV disease: results from the Multicenter AIDS Cohort Study. Qual Life Res 2000 9 55-63
11. Spencer S, Calverley P M., Sherwood Burge P, Jones P W., ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 163 122-128
12. Tsuji-Hayashi Y, Sizer Fitts S, Takai I et al. Health-related quality of life among dialysis patients in Seattle and Aichi. Am J Kidney Dis 2001 37 987-996
13. Scadding J G. Prognosis of intrathoracic sarcoidosis in England: a review of 136 cases after five years observation. BMJ 1961 2 1165-1172
14. Siltzbach L E., James D G., Neville E et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974 57 847-852
15. Sones M, Israel H L. Course and prognosis of sarcoidosis. Am J Med 1960 29 84-93
16. Israel H L., Fouts D W., Beggs R A. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973 107 609-614
17. Hunninghake G W., Costabel U, Ando M et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999 16 149-173
18. Gottlieb J E., Israel H L., Steiner R M., Triolo J, Patrick H. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest 1997 111 623-631 (Pubitemid 27132936)
19. Hunninghake G W., Gilbert S, Pueringer R et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994 149 (4 Pt 1) 893-898
20. Baughman R P., Lower E E., du Bois R M. Sarcoidosis. Lancet 2003 361 1111-1118
21. Eule H, Weinecke A, Roth I, Wuthe H. The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis: late results of a continuing clinical study. Ann N Y Acad Sci 1986 465 695-701
22. Selroos O, Sellergren T L. Corticosteroid therapy of pulmonary sarcoidosis: a prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis 1979 60 215-221
23. Zaki M H., Lyons H A., Leilop L, Huang C T. Corticosteroid therapy in sarcoidosis: a five-year, controlled follow-up study. N Y State J Med 1987 87 496-499
24. Grunewald J, Shigematsu M, Nagai S et al. T-cell receptor V gene expression in HLA-typed Japanese patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1995 151 151-156
25. Baughman R P., Costabel U, du Bois R M. Treatment of sarcoidosis. Clin Chest Med 2008 29 533-548 ix-x
26. Judson M A. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999 115 1158-1165
27. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, Finnish Pulmonary Sarcoidosis Study Group. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Chest 1999 116 424-431
28. Gibson G J., Prescott R J., Muers M F. et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996 51 238-247
29. Lynch J P. III, Kazerooni E A., Gay S E. Pulmonary sarcoidosis. Clin Chest Med 1997 18 755-785
30. Mihailovic-Vucinic V, Jovanovic D. Pulmonary sarcoidosis. Clin Chest Med 2008 29 459-473 viii-ix
31. Newman L S., Rose C S., Maier L A. Sarcoidosis. N Engl J Med 1997 336 1224-1234
32. Nagai S, Shigematsu M, Hamada K, Izumi T. Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med 1999 5 293-298
33. Neville E, Walker A N., James D G. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983 52 525-533
34. Ma J, Salazar A, Manresa F. Clinical factors predicting persistence of activity in sarcoidosis: a multivariate analysis of 193 cases. Respiration 1994 61 219-225
35. Rmer F K. Presentation of sarcoidosis and outcome of pulmonary changes. Dan Med Bull 1982 29 27-32
36. Grunewald J, Eklund A. Lfgrens syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med 2009 179 307-312
37. Mller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999 14 1117-1122
38. Hillerdal G, Nu E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis: a 15-year European study. Am Rev Respir Dis 1984 130 29-32
39. Pietinalho A, Ohmichi M, Lfroos A B., Hiraga Y, Selroos O. The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan: a comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis 2000 17 158-166
40. Baughman R P., Winget D B., Bowen E H., Lower E E. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 1997 14 154-158
41. Ma J, Gmez-Vaquero C, Montero A et al. Lfgrens syndrome revisited: a study of 186 patients. Am J Med 1999 107 240-245
42. Sharma O P. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis 1993 147 (6 Pt 1) 1598-1600
43. Baughman C, Morin-Leisk J, Lee T. Nucleoside diphosphate kinase B (NDKB) scaffolds endoplasmic reticulum membranes in vitro. Exp Cell Res 2008 314 2702-2714
44. Vestbo J, Viskum K. Respiratory symptoms at presentation and long-term vital prognosis in patients with pulmonary sarcoidosis. Sarcoidosis 1994 11 123-125
45. Judson M A. Lung transplantation for pulmonary sarcoidosis. Eur Respir J 1998 11 738-744
46. Sulica R, Teirstein A S., Kakarla S, Nemani N, Behnegar A, Padilla M L. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005 128 1483-1489
47. Ziegenhagen M W., Rothe M E., Schlaak M, Mller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 2003 21 407-413
48. Baughman R P., Teirstein A S., Judson M A. et al, Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001 164 (10 Pt 1) 1885-1889
49. Israel H L., Karlin P, Menduke H, DeLisser O G. Factors affecting outcome of sarcoidosis. Influence of race, extrathoracic involvement, and initial radiologic lung lesions. Ann N Y Acad Sci 1986 465 609-618
50. Mihailovic-Vucinic V, Zugic V, Videnovic-Ivanov J. New observations on pulmonary function changes in sarcoidosis. Curr Opin Pulm Med 2003 9 436-441
51. Winterbauer R H., Hutchinson J F. Use of pulmonary function tests in the management of sarcoidosis. Chest 1980 78 640-647
52. Grutters J C., van den Bosch J M. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006 28 627-636
53. Baughman R P., Drent M, Kavuru M et al, Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006 174 795-802
54. Johns C J., Michele T M. The clinical management of sarcoidosis: a 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999 78 65-111
55. Yeager H, Rossman M D., Baughman R P. et al, ACCESS Research Group. Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 2005 22 147-153
56. Chang B, Steimel J, Moller D R. et al. Depression in sarcoidosis. Am J Respir Crit Care Med 2001 163 329-334
57. Michielsen H J., Peros-Golubicic T, Drent M, De Vries J. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration 2007 74 401-405
58. de Kleijn W P., De Vries J, Lower E E., Elfferich M D., Baughman R P., Drent M. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009 15 499-506
59. Drent M, Wirnsberger R M., de Vries J, van Dieijen-Visser M P., Wouters E F., Schols A M. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999 13 718-722
60. Wirnsberger R M., de Vries J, Wouters E F., Drent M. Clinical presentation of sarcoidosis in the Netherlands an epidemiological study. Neth J Med 1998 53 53-60
61. De Vries J, Michielsen H, Van Heck G L., Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004 9 (Pt 3) 279-291
62. Lower E E., Harman S, Baughman R P. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008 133 1189-1195
63. Baughman R P., Malhorta A, Surdulescu V, Lower E E. Armodafinil (r-modafinil) for fatigue in sarcoidosis: not just treating hypersomnolence [abstract]. Chest 2009 136 128S
64. Turner G A., Lower E E., Corser B C., Gunther K L., Baughman R P. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997 14 (1) 61-64
65. Mughal M M., Golish J, Kavuru M, Aladesanmi O, Ivansek N, Culver D A. Sleep apnea in sarcoidosis [abstract]. Chest 2005 128 230S
66. Shah R N., Mills P R., George P J., Wedzicha J A. Upper airways sarcoidosis presenting as obstructive sleep apnoea. Thorax 1998 53 232-233
67. Hoitsma E, De Vries J, van Santen-Hoeufft M, Faber C G., Drent M. Impact of pain in a Dutch sarcoidosis patient population. Sarcoidosis Vasc Diffuse Lung Dis 2003 20 33-39
68. Hoitsma E, Faber C G., van Kroonenburgh M J. et al. Association of small fiber neuropathy with cardiac sympathetic dysfunction in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005 22 43-50 (Pubitemid 40444733)
69. Hoitsma E, Faber C G., van Santen-Hoeufft M, De Vries J, Reulen J P., Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006 23 73-77
70. Baughman R P., Judson M A., Teirstein A et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006 99 307-315
71. Paramothayan S, Jones P W. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002 287 1301-1307
72. Paramothayan N S., Lasserson T J., Jones P W. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005 (2) CD001114
73. Winterbauer R H., Kirtland S H., Corley D E. Treatment with corticosteroids. Clin Chest Med 1997 18 843-851
74. Kataria Y P. Chlorambucil in sarcoidosis. Chest 1980 78 36-43
75. Ma J. Nuclear imaging. 67Gallium, 201thallium, 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography. Clin Chest Med 1997 18 799-811
76. Ziegenhagen M W., Rothe M E., Zissel G, Mller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002 19 185-190
77. Sodhi M, Pearson K, White E S., Culver D A. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009 103 268-273
78. Lower E E., Broderick J P., Brott T G., Baughman R P. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997 157 1864-1868
79. Alberts C, van der Mark T W., Jansen H M., Dutch Study Group on Pulmonary Sarcoidosis. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Eur Respir J 1995 8 682-688
80. Erkkil S, Frseth B, Hellstrm P E. et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis 1988 5 106-110
81. Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994 236 285-290
82. Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993 10 56-61
83. du Bois R M., Greenhalgh P M., Southcott A M., Johnson N M., Harris T A. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999 13 1345-1350
84. Baughman R P., Iannuzzi M C., Lower E E. et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002 19 198-204
85. James D G., Carstairs L S., Trowell J, Sharma O P. Treatment of sarcoidosis: report of a controlled therapeutic trial. Lancet 1967 2 526-528
86. Schutt A C., Bullington W M., Judson M A. Pharmacotherapy for pulmonary sarcoidosis: a delphi consensus study. Respir Med 2010 104 713-723
87. McKinzie B P., Bullington W M., Mazur J E., Judson M A. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 2010 339 1-4
88. Yazaki Y, Isobe M, Hiroe M et al, Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001 88 1006-1010
89. Goldstein D S., Williams M H. Rate of improvement of pulmonary function in sarcoidosis during treatment with corticosteroids. Thorax 1986 41 473-474
90. Baughman R P., Winget D B., Lower E E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000 17 60-66
91. Yale S H., Limper A H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996 71 5-13
92. Greenberg J D., Reed G, Kremer J M. et al, CORRONA Investigators. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010 69 380-386
93. Ellerin T, Rubin R H., Weinblatt M E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003 48 3013-3022
94. Rizzato G, Tosi G, Mella C, Montemurro L, Zanni D, Sisti S. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Sarcoidosis 1988 5 93-98
95. Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, Rizzato G. Bone loss in prednisone treated sarcoidosis: a two-year follow-up. Ann Ital Med Int 1990 5 (3 Pt 1) 164-168
96. van Staa T P., Leufkens H G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002 13 777-787
97. van Staa T P., Leufkens H G., Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000 39 1383-1389
98. Devogelaer J P., Goemaere S, Boonen S et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006 17 8-19
99. Adler R A., Hochberg M C. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003 163 2619-2624
100. Adams J S., Diz M M., Sharma O P. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med 1989 111 437-438
101. Siltzbach L E., Teirstein A S. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl 1964 425 302-308
102. Zic J A., Horowitz D H., Arzubiaga C, King L E. Jr. Treatment of cutaneous sarcoidosis with chloroquine: review of the literature. Arch Dermatol 1991 127 1034-1040
103. Baltzan M, Mehta S, Kirkham T H., Cosio M G. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999 160 192-197
104. Chan E S., Cronstein B N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002 4 266-273
105. Baughman R P., Lower E E. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990 142 (6 Pt 1) 1268-1271
106. Baughman R P., Lower E E. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997 14 121-130
107. Lower E E., Baughman R P. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995 155 846-851
108. Veien N K., Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol 1977 97 213-216
109. Dev S, McCallum R M., Jaffe G J. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999 106 111-118
110. Baughman R P., Lower E E. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 1999 54 742-746
111. Webster G F., Razsi L K., Sanchez M, Shupack J L. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991 24 451-454
112. Jundt J W., Browne B A., Fiocco G P., Steele A D., Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993 20 1845-1849
113. van Ede A E., Laan R F., Rood M J. et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001 44 1515-1524
114. Morgan S L., Baggott J E., Vaughn W H. et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994 121 833-841
115. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009 68 1086-1093
116. Lewis S J., Ainslie G M., Bateman E D. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999 16 87-92
117. Pacheco Y, Marechal C, Marechal F, Biot N, Perrin Fayolle M. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis 1985 2 107-113
118. Lennard L, Van Loon J A., Weinshilboum R M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989 46 149-154
119. Bhat P, Cervantes-Castaeda R A., Doctor P P., Anzaar F, Foster C S. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm 2009 17 185-190
120. Golshayan D, Pascual M, Vogt B. Mycophenolic acid formulations in adult renal transplantationupdate on efficacy and tolerability. Ther Clin Risk Manag 2009 5 341-351
121. Baughman R P., Lower E E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004 21 43-48
122. Emery P, Breedveld F C., Lemmel E M. et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000 39 655-665
123. Bradley D A., Lower E E., Baughman R P. Diagnosis and management of spinal cord sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006 23 58-65
124. Doty J D., Mazur J E., Judson M A. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003 124 2023-2026
125. Kavanaugh A F., Andrew S L., Cooper B, Lawrence E C., Huston D P. Cyclosporine therapy of central nervous system sarcoidosis. Am J Med 1987 82 387
126. Stern B J., Schonfeld S A., Sewell C, Krumholz A, Scott P, Belendiuk G. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol 1992 49 1065-1072
127. Oh J Y., Wee W R. Cyclosporine for conjunctival sarcoidosis. Ophthalmology 2008 115 222
128. Akpek E K., Ilhan-Sarac O, Green W R. Topical cyclosporin in the treatment of chronic sarcoidosis of the conjunctiva. Arch Ophthalmol 2003 121 1333-1335
129. Bielory L, Frohman L P. Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophthalmology 1991 98 1732-1736
130. Suarez-Almazor M E., Belseck E, Shea B, Wells G, Tugwell P. Cyclophosphamide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000 CD001157
131. Baughman R P., Lower E E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001 18 70-74
132. Yee A M., Pochapin M B. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001 135 27-31
133. Rossman M D., Newman L S., Baughman R P. et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006 23 201-208
134. Judson M A., Baughman R P., Costabel U et al, Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008 31 1189-1196
135. Carter J D., Valeriano J, Vasey F B., Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004 117 277-279
136. Doty J D., Mazur J E., Judson M A. Treatment of sarcoidosis with infliximab. Chest 2005 127 1064-1071
137. Moravan M, Segal B M. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009 72 337-340
138. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma O P. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006 100 2053-2059
139. Baughman R P., Lower E E., Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008 25 76-89
140. Keane J, Gershon S, Wise R P. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 345 1098-1104
141. Wallis R S., Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004 39 1254-1255 (Pubitemid 40169331)
142. Chung E S., Packer M, Lo K H., Fasanmade A A., Willerson J T., Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003 107 3133-3140
143. Sandborn W J. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003 5 501-505
144. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004 126 1593-1610 (Pubitemid 38649876)
145. Panselinas E, Rodgers J K., Judson M A. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 2009 14 522-528
146. Thielen A M., Barde C, Saurat J H., Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology 2009 219 59-62
147. Marnane M, Lynch T, Scott J, Stack J, Kelly P J. Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol 2009 256 139-140
148. Bartelds G M., Wijbrandts C A., Nurmohamed M T. et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007 66 921-926
149. Utz J P., Limper A H., Kalra S et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003 124 177-185
150. Baughman R P., Lower E E., Bradley D A., Raymond L A., Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005 128 1062-47
151. Kudrin A, Chilvers E R., Ginawi A et al. Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol 2007 34 648-649
152. Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol 2007 26 1969-1971 (Pubitemid 47516989)
153. Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 2003 124 1526-1532
154. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997 155 1665-1669
155. Park M K., Fontana J R., Babaali H et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009 26 121-131
156. Tavares J L., Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw R J. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 1997 91 31-39
157. Baughman R P., Judson M A., Teirstein A S., Moller D R., Lower E E. Thalidomide for chronic sarcoidosis. Chest 2002 122 227-232
158. Hoyle J C., Newton H B., Katz S. Prognosis of refractory neurosarcoidosis altered by thalidomide: a case report. J Med Case Reports 2008 2 27
159. Hammond E R., Kaplin A I., Kerr D A. Thalidomide for acute treatment of neurosarcoidosis. Spinal Cord 2007 45 802-803
160. Judson M A., Silvestri J, Hartung C, Byars T, Cox C E. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006 23 51-57
161. Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001 137 69-73
162. Orens J B., Estenne M, Arcasoy S et al, Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 updatea consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006 25 745-755
163. Milman N, Burton C, Andersen C B., Carlsen J, Iversen M. Lung transplantation for end-stage pulmonary sarcoidosis: outcome in a series of seven consecutive patients. Sarcoidosis Vasc Diffuse Lung Dis 2005 22 222-228
164. Pigula F A., Griffith B P., Zenati M A., Dauber J H., Yousem S A., Keenan R J. Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg 1997 64 1630-1634
165. Johnson B A., Duncan S R., Ohori N P. et al. Recurrence of sarcoidosis in pulmonary allograft recipients. Am Rev Respir Dis 1993 148 1373-1377
166. Baughman R P. Methotrexate for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998 15 147-149